首页> 中国专利> 一种抑制人脑胶质瘤的靶向linc01023基因的抑制剂及其应用

一种抑制人脑胶质瘤的靶向linc01023基因的抑制剂及其应用

页面导航

摘要
著录项
相似文献

摘要

本发明属于生物基因治疗领域，具体涉及一种抑制脑胶质瘤的靶向linc01023基因的抑制剂及其应用。该靶向抑制剂的核苷酸序列为：5’‑CTCCTTCTGACGGCGGAAA‑3’（SEQ ID No.1）。本发明为了解决抑制脑胶质瘤的增殖迁移侵袭基因治疗问题，以RNAi技术为基础，通过人工合成linc01023靶向shRNA，可以靶向作用于linc01023基因，促进其降解，达到使linc01023基因表达降低的结果，为临床上治疗脑胶质瘤提供了新的思路。

著录项

公开/公告号CN110157708B

专利类型发明专利
公开/公告日2021-03-02

原文格式PDF
申请/专利权人中国医科大学附属盛京医院;
展开▼

申请/专利号CN201910455371.1
发明设计人于明军;于诗嘉;陈铎;关俊宏;
展开▼

申请日2019-05-29
分类号C12N15/113(20100101);A61K31/713(20060101);A61P35/00(20060101);A61P35/04(20060101);
代理机构21107 沈阳亚泰专利商标代理有限公司;
代理人史力伏
地址 110004 辽宁省沈阳市和平区三好街36号
入库时间 2022-08-23 11:33:45

相似文献

专利
中文文献
外文文献

1. 一种抑制人脑胶质瘤的靶向linc01023基因的抑制剂及其应用 [P] . 中国专利： CN110157708B . 2021.03.02
2. 一种抑制人恶性脑胶质瘤的靶向linc00998基因的抑制剂及其应用 [P] . 中国专利： CN110257377A . 2019-09-20
3. Polinucleotu00eddeo insulated tape of expression, host cell, isolated transgenic non-human animal polypeptide, which has been modified to express a polypeptide mutant with resistance to ALK, antibody that binds specifically to a polypeptide mutant with resistance to ALK, kit p For detection of a mutation with resistance to ALK inhibitor in a biological sample, and,Methods for evaluating a biological sample as a mutation with resistance to ALK inhibitor, for diagnosing a cancer that is resistant to or is likely to develop resistance to at least one inhibitor of kinase small molecule ALK, to evaluate a biological sample that Anto a mutation with resistance to ALK inhibitor.For diagnosing a cancer that is resistant to or is likely to develop resistance to at least one inhibitor of kinase small molecule ALK, to assess the biological sample as a mutation with resistance to ALK inhibitor, a cancer that is resistant to dianosticar Or is likely to develop resistance to PF - 02341066 in a pati [P] . BR112012026239A2 . 2016-11-29

机译：修饰的多聚核苷酸绝缘带，宿主细胞，分离的转基因非人类动物多肽，经过修饰以表达对ALK具有抗性的多肽突变体，与对ALK具有抗性的多肽突变体特异性结合的抗体，试剂盒p用于检测生物样品中对ALK抑制剂具有抗性的突变，以及用于评估生物样品为对ALK抑制剂具有抗性的突变的方法，用于诊断对至少一种对ALK抑制剂具有抗性或可能发展出抗性的癌症激酶小分子ALK，以评估Anto对ALK抑制剂具有抗性的突变的生物样品。用于诊断对至少一种激酶小分子ALK抑制剂具有抗药性或可能产生抗性的癌症，以评估该生物样品作为对ALK抑制剂有抗性的突变，即对狄诺司他抗性或可能对PF产生抗药性的癌症-02341066
4. isolated polynucleotide, expression cassette, host cell, isolated polypeptide, non-human transgenic animal that has been altered to express an alkali resistant mutant polypeptide, an antibody that specifically binds to an alkali resistant mutant polypeptide, a mutation detection kit alk inhibitor resistance in a biological sample, and methods for evaluating a biological sample for an alk inhibitor resistance mutation to diagnose cancer that is resistant to or likely to develop resistance to at least one alkaline inhibitor. small alk molecule kinase, to evaluate a biological sample for an alk inhibitor resistance mutation, to diagnose cancer that is resistant to or likely to develop resistance to pf-02341066 in a patient, to specifically reduce expression of an alk-resistant mutant to treat cancer associated with activating aberrant loop capacity that is resistant to at least one small molecule alk kinase inhibitor treating an aberrant cancer that is resistant to pf-02341066, identifyin [P] . BR112012026239A2 . 2018-06-26

机译：分离的多核苷酸，表达盒，宿主细胞，分离的多肽，已被改变以表达耐碱突变体多肽的非人类转基因动物，与耐碱突变体多肽特异性结合的抗体，突变检测试剂盒生物样品，以及用于评估生物样品中是否存在对烷基抑制剂的抗性突变以诊断对至少一种碱性抑制剂有抗药性或可能发展出抗药性的癌症的方法。小分子激酶，用于评估生物学样品中是否具有抑制碱性磷酸酶抑制剂的突变，以诊断对患者具有抗药性或可能对pf-02341066产生抗药性的癌症，从而特异性降低抗癌突变体的表达以治疗癌症与激活抗至少一种小分子烷基激酶抑制剂的异常环路能力有关，该抑制剂治疗对pf-02341066有抵抗力的异常癌症
5. APPLICATION OF PEG-INTERFERON AND PROTOONCOGENE PRODUCT TARGETING INHIBITOR IN SYNERGISTIC INHIBITION OF TUMORS [P] . WO2021062961A1 . 2021-04-08

机译： PEG-干扰素和原虫基因烯产物靶向抑制剂在肿瘤协同抑制中的应用